Premium
Low‐dose versus standard‐dose four‐factor prothrombin complex concentrate for factor‐Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage
Author(s) -
Cascone Ava E.,
Daley Mitchell J.,
Pan Neil,
PadillaTolentino Eimeira,
Milling Truman J.
Publication year - 2021
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.2525
Subject(s) - prothrombin complex concentrate , prothrombin complex , medicine , intracranial hemorrhages , anesthesia , coagulation , warfarin , atrial fibrillation , subarachnoid hemorrhage
Study Objectives Current neurocritical care guidelines recommend 50 IU/kg four‐factor prothrombin complex concentrate (4PCC) for factor Xa inhibitor (FXaI) reversal in intracranial hemorrhage (ICH) based on few clinical studies conducted among non‐ICH subjects. Two recent studies suggest that low‐dose (25 IU/kg) 4PCC may be similar to 50 IU/kg in reversal of FXaI in ICH, and both 25 and 50 IU/kg doses are used in clinical practice for this indication. To our knowledge, no studies have directly compared 25 IU/kg versus 50 IU/kg 4PCC for FXaI reversal in ICH. The purpose of this study is to determine whether there is a difference in hemostatic efficacy between 25 IU/kg versus 50 IU/kg 4PCC for FXaI reversal in ICH. Design This multicenter, retrospective cohort study was performed in five hospitals in central Texas from November 2013 to December 2019. Data Source Patients were identified with a medication use report of 4PCC and were classified in the low‐ or standard‐dose group based on whether the 25 IU/kg or 50 IU/kg dose was received, respectively. Patients A total of 93 patients were included (25 IU/kg, n = 62; 50 IU/kg, n = 31). Measurements and Main Results There was no difference in hemostatic efficacy between groups (82.3% low dose vs. 83.9% standard dose, p = 0.846). No differences were identified in‐hospital mortality, length of stay, thrombotic events, or the need for surgery or additional blood products between groups. Conclusion For the reversal of FXaI in ICH, a 25 IU/kg dose may be an effective alternative to 50 IU/kg 4PCC dosing.